Semaglutide May Have Reactivated a Dormant Brain Parasite by Dampening Protective Inflammation | Research

The takeaway

A 64-year-old woman on semaglutide developed speech problems from reactivation of a dormant brain parasite (neurocysticercosis), possibly because the drug's anti-inflammatory effects weakened the immune response keeping the cysts in check.

Decades-dormant infection reactivated
Neurocysticercosis cysts that had been dormant for decades reactivated after semaglutide use, potentially because the drug dampened the brain's protective inflammatory response

What the researchers found

A patient on semaglutide developed anomic aphasia (difficulty naming objects) — a rare neurological manifestation — from reactivation of neurocysticercosis cysts that had been dormant for decades. Brain imaging confirmed localized cystic changes. The proposed mechanism is that semaglutide attenuated the protective inflammatory response maintained by astrocytes and microglia around the dormant cysts, allowing reactivation. Treatment with antiparasitic agents and corticosteroids led to marked clinical improvement.

Why it matters

As semaglutide and other GLP-1 drugs are prescribed to millions of people worldwide — including in regions where parasitic infections like neurocysticercosis are endemic — this case raises a novel safety signal. GLP-1 receptor agonists have well-documented anti-inflammatory effects in the brain, which are being explored as benefits for Alzheimer's and other neurological conditions. But this case suggests those same anti-inflammatory effects could be a risk in patients harboring dormant infections kept in check by chronic inflammation.

How the study worked

Single case report of a 64-year-old female presenting with anomic aphasia while on semaglutide, with confirmed neurocysticercosis reactivation on brain imaging. The temporal relationship between semaglutide use and symptom onset, along with the known anti-neuroinflammatory effects of GLP-1 receptor agonists, was used to hypothesize the causal mechanism.

What this study cannot tell us

This is a single case report — the lowest level of clinical evidence. The causal link between semaglutide and NCC reactivation is hypothetical and cannot be confirmed without larger observational studies. Other factors could have triggered the reactivation. The proposed mechanism (astrocyte/microglial modulation) is plausible but not proven in this case. Case reports can generate hypotheses but not establish risk levels.

How to read the evidence

This is a single case report representing the lowest level of clinical evidence. While it generates an important hypothesis about GLP-1RA immune modulation and dormant infection reactivation, the causal relationship cannot be confirmed without systematic investigation.

When this study was published

Published in 2025, this case report arrives at a critical time as GLP-1 drug prescriptions surge globally, including in regions where parasitic infections like neurocysticercosis are common.

The bigger picture

This case adds nuance to the increasingly complex picture of GLP-1 receptor agonist effects beyond metabolism. While semaglutide's anti-neuroinflammatory properties are being hailed as potentially neuroprotective, this report demonstrates that dampening brain inflammation isn't universally beneficial. In patients with dormant infectious granulomas, cysts, or other pathology controlled by chronic immune surveillance, GLP-1-mediated immune modulation could theoretically allow disease reactivation — a consideration analogous to the known reactivation risks with other immunomodulatory therapies.

Questions still open

Should patients from endemic regions be screened for dormant neurocysticercosis before starting GLP-1 receptor agonists?
Could semaglutide's anti-neuroinflammatory effects reactivate other dormant CNS infections like tuberculosis or toxoplasmosis?
Is this a class effect of all GLP-1 receptor agonists, or specific to semaglutide's CNS penetration?

Common questions

What is neurocysticercosis?

Neurocysticercosis is a brain infection caused by larvae of the pork tapeworm (Taenia solium). It is the leading cause of acquired epilepsy in developing countries. Cysts can remain dormant in the brain for years or decades, kept in check by the immune system's inflammatory response around them. If this immune surveillance weakens, the cysts can reactivate and cause symptoms.

Should I worry about this if I'm taking Ozempic?

This is a single case report, and the risk — if real — would primarily apply to people who harbor dormant brain parasitic cysts from prior neurocysticercosis infection. This is most relevant for people from regions where the pork tapeworm is common. If you have a known history of neurocysticercosis, discussing this with your doctor before starting GLP-1 drugs would be prudent. For most people taking these medications, this does not represent a common concern.

Read the original research

Echoes of Dormancy: Anomic Aphasia Unveils Neurocysticercosis Reactivation in a Patient on Semaglutide.

NeuroSci, 6(2)

View on PubMed ↗Publisher’s paper ↗

Citation

Osorio Borjas, Marcos; Hernandez, Robert J; Lopez-Lacayo, Angelo; Laffita Perez, Dalina; Oliva, Yanie; Mercado, Julio; Hussain, Hussain. (2025). Echoes of Dormancy: Anomic Aphasia Unveils Neurocysticercosis Reactivation in a Patient on Semaglutide.. NeuroSci, 6(2). https://doi.org/10.3390/neurosci6020040